Hypertension (immediate-release)
- 2.5 mg PO bid
- maintenance 2.5-10mg PO bid; Max: 20 mg/day
Hypertension (controlled-release)
- 5 mg PO qd
- maintenance: 5-10mg qd; Max: 20 mg/day
- Safety and effectiveness in pediatric patients have not been established
Hypertension (immediate-release)
Hypertension (controlled-release)
Renal Dose Adjustment
Hepatic Dose Adjustment
Cautions: Use cautiously in
Dynacirc, Dynacirc CR interacts with :
Pregnancy Category:C
Breastfeeding: Safety unknown. Because no information is available on the use of isradipine during breastfeeding, an alternate drug may be preferred. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 9 March 2011). Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
US Trade Name(s)
US Availability
isradipine (generic)
Dynacirc
Dynacirc CR
Canadian Trade Name(s)
Canadian Availability
UK Trade Name(s)
UK Availability
Prescal
Australian Trade Name(s)
Australian Availability
Pricing data from www.DrugStore.com in U.S.A.
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
